human HLA-DR

Contents: PerCP-Cy5.5 anti-human HLA-DR
Catalog Number: 45-9956
Formulation: Phosphate buffer pH 7.2,
150 mM NaCl, 0.09% NaN₃, 0.1% gelatin
Storage Conditions: Store at 4°C.
DO NOT FREEZE.
LIGHT-SENSITIVE MATERIAL.
Clone: LN3
Isotype: Mouse IgG2b, κ

Prices for This Product*
Cat. No.	Size	Price	Qty	Action
45-9956-71	25 tests	$150
45-9956-73	100 tests	$348

*International customers: Please contact your distributor for region specific pricing. May not be available for sale in all countries (see below).

Staining of peripheral blood mononuclear cells with 0.015 μg of PerCP-Cy5.5 Mouse IgG2b Iso Cntrl (cat. 45-4732) (open histogram) or PerCP-Cy5.5 anti-human HLA-DR (LN3) (colored histogram). Cells in the lymphocyte gate were used for analysis.

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
11-9956	Fluorescein isothiocyanate (FITC) anti-human HLA-DR	488	518	FC
12-9956	PE anti-human HLA-DR	488	575	FC
13-9956	Biotin anti-human HLA-DR	N/A	N/A	FC
14-9956	Affinity Purified anti-human HLA-DR	N/A	N/A	FC IHC
15-9956	Phycoerythrin-Cy5 (PE-Cy5) anti-human HLA-DR	488	670	FC
17-9956	APC anti-human HLA-DR	633	660	FC
25-9956	Phycoerythrin-Cy7 (PE-Cy7) anti-human HLA-DR	488	760	FC
45-9956	PerCP-Cy5.5 anti-human HLA-DR	488	690	FC
56-9956	Alexa Fluor® 700 anti-human HLA-DR (APC-Cy5.5 Equivalent)	633	723	FC

PerCP contained in this product is protected by patents owned by Becton, Dickinson & Company (European patent 0314406, or Japanese Patent JP1888759). This product will not be sold or shipped to customers in France, Germany, Italy, United Kingdom or Japan until the pertinent patents are no longer in effect (October 21, 2008).

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

The LN3 mAb reacts with the human major histocompatibility complex (MHC) class II, HLA-DR. HLA-DR is expressed on the surface of human antigen presenting cells (APC) including B cells, monocytes, macrophages, DCs, and activated T cells. HLA-DR is a heterodimeric transmembrane protein composed of α and β subunits and plays an important role in the presentation of peptides to CD4⁺ T lymphocytes.

Applications Reported

For research use only, not for diagnostic or therapeutic use. This LN3 antibody has been reported for use in flow cytometric analysis.

Applications Tested

This LN3 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 20 μl (0.015 μg) per million cells in a 100 μl total staining volume.

References

Fullen, D. R. and J. T. Headington (1998). "Factor XIIIa-positive dermal dendritic cells and HLA-DR expression in radial versus vertical growth-phase melanomas [see comments]." J Cutan Pathol 25(10): 553-8.
Hua, Z. X., K. E. Tanaka, et al. (1998). "Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung." Hum Pathol 29(12): 1441-6.
Ioachim, H. L., S. E. Pambuccian, et al. (1996). "Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications." Am J Surg Pathol 20(1): 64-71.
Davey, F. R., S. Olson, et al. (1988). "The immunophenotyping of extramedullary myeloid cell tumors in paraffin-embedded tissue sections." Am J Surg Pathol 12(9): 699-707.
Norton, A. J. and P. G. Isaacson (1987). "Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue." Am J Pathol 128(2): 225-40.

Related Products

Cat. 45-4732 PerCP-Cy5.5 Mouse IgG2b Isotype Control